Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

7.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.4K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Higher Tumor Mutational Burden Is Associated With Inferior Outcomes Among Pediatric Patients With Neuroblastoma.

Higher tumor mutational burden is associated with inferior outcomes among pediatric patients with neuroblastoma.

Ya-Hsuan Chang1, Chih-Hsiang Yu2,3, Meng-Yao Lu4,5

  • 1Institute of Molecular and Genomic Medicine, National Health Research Institute, Miaoli, Taiwan.

Pediatric Blood & Cancer
|July 5, 2024

Related Experiment Videos

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.1K
Zebrafish Model of Neuroblastoma Metastasis
05:20

Zebrafish Model of Neuroblastoma Metastasis

Published on: March 14, 2021

2.8K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

View abstract on PubMed

Summary
This summary is machine-generated.

Tumor mutational burden, MYCN amplification, and chromosome 3p deletion are key prognostic markers for neuroblastoma patients. Identifying these genetic markers improves risk stratification and treatment decisions for better patient outcomes.

Area of Science:

  • Pediatric Oncology
  • Cancer Genomics
  • Translational Research

Background:

  • Neuroblastoma is a diverse pediatric cancer with varied outcomes.
  • Accurate prognostic markers are crucial for effective risk stratification and treatment planning.

Purpose of the Study:

  • To identify prognostic genetic markers for neuroblastoma patients treated under the TPOG N2002 protocol.
  • To enhance risk stratification and guide treatment strategies for improved patient outcomes.

Main Methods:

  • Deep sequencing of 113 genes in 53 primary and 11 paired relapse neuroblastoma specimens.
  • Multiplex ligation-dependent probe amplification (MLPA) to analyze copy-number variations.
  • Identification of genetic variations associated with patient survival.
Keywords:
ALK variationsMYCN amplificationsTMBneuroblastoma

Related Experiment Videos

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.1K
Zebrafish Model of Neuroblastoma Metastasis
05:20

Zebrafish Model of Neuroblastoma Metastasis

Published on: March 14, 2021

2.8K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

Main Results:

  • 128 variations linked to survival were identified; relapse specimens had more variations.
  • Higher tumor mutational burden (≥10) correlated with increased event and mortality risk (p < .0001).
  • Tumor mutational burden, MYCN amplification, and 3p deletion were independent prognostic factors.

Conclusions:

  • Genome sequencing for tumor mutational burden and ALK variations improves neuroblastoma risk classification.
  • These genetic insights can inform personalized treatment approaches for neuroblastoma.
  • Identifying prognostic markers like MYCN amplification and 3p deletion aids in managing this pediatric malignancy.
risk‐directed therapy